姜德福, 程光惠, 韩冬梅. 斯普林配合放化疗治疗115例高危乳腺癌的临床观察[J]. 中国肿瘤临床, 2004, 31(16): 940-942.
引用本文: 姜德福, 程光惠, 韩冬梅. 斯普林配合放化疗治疗115例高危乳腺癌的临床观察[J]. 中国肿瘤临床, 2004, 31(16): 940-942.
Jiang De-fu, Cheng Guang-hui, Han Dong-mei. The Clinical Study in Patients with High-risk Brest Cancer after Modified Radical Mastectomy Treated with Sipulin Combined with Chemotherapy and Radiotherapy[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 31(16): 940-942.
Citation: Jiang De-fu, Cheng Guang-hui, Han Dong-mei. The Clinical Study in Patients with High-risk Brest Cancer after Modified Radical Mastectomy Treated with Sipulin Combined with Chemotherapy and Radiotherapy[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 31(16): 940-942.

斯普林配合放化疗治疗115例高危乳腺癌的临床观察

The Clinical Study in Patients with High-risk Brest Cancer after Modified Radical Mastectomy Treated with Sipulin Combined with Chemotherapy and Radiotherapy

  • 摘要: 目的:观察斯普林配合放化疗治疗术后高危乳腺癌患者的疗效。方法:115例高危乳腺癌患者采用信封法随机分为两组观察组60例,采用斯普林+放化疗;对照组55例,采用放化疗。观察斯普林对患者卡氏评分、外周血象的影响及治疗后的5年无瘤生存率、局部复发率、远处转移率。结果:治疗后观察组患者卡氏评分明显优于对照组(P<0.05)。观察组治疗后与治疗前比较Hb,WBC,RBC,PLT值无明显下降(P>0.05),而对照组四项指标与治疗前相比明显降低(P<0.01),治疗后观察组血象高于对照组(P<0.05)。观察组与对照组5年无瘤生存率分别为78.33%,63.64%(χ2=3.16,P>0.05),局部复发率分别为10.00%,16.36%(χ2=4.82,P<0.05),两组远处转移率分别为11.67%,20.00%(χ2=4.26,P<0.05)。结论:斯普林具有升高外周血象、改善生存质量及抑制肿瘤细胞增殖的抗肿瘤作用。

     

    Abstract: objective : Observe the outcome of chemoradiotherapy combined with sipulin in the patients with high-risk breast cancer after the modified radical mastectomy and its affection to Karnofsky performance scale (KPS) and peripheral hemogram. Methods : 115 cases with high-risk breast cancer were randomized into two groups, one was study group with sipulin combined with chemoradiotherapy, another was control group only with chemoradiotherapy. 0bserve the affection to KPS, the peripheral hemogram and 5-year tumor free survival rate, local regional recurrence rate, distant metastasis rate. Results : The valure of KPS was lower in control group than that in study group after the treatment (P<0.05). The value of HB, WBC, RBC, PLT wasn't statistically different in study group before and after the treatment (P>0.05). But the value of which was statistically different between two groups after the treatment and in control group before and after the treatment. The 5-year tumor free survival rate were78.33%, 63.64% in study group and control group respectively (P>0.05), the local regional recurrence rate were10%,16.36% respectively (P<0.05), the distant metastasis rate were 11.67%, 20% respectively (P<0.05). Conclusions : Sipulin can improve life quality, promote peripheral hemogram and control the proliferation of the tumor cell.

     

/

返回文章
返回